Media Coverage

On this episode I talked to Michael Racke, MD Medical Director of Neurology at Quest Diagnostics. Michael discusses promising advancements in our understanding and treatment of Alzheimer’s disease. He explains how imaging and biomarkers have allowed earlier and more accurate diagnosis, moving from just a clinical picture to actually visualizing amyloid plaques and tau tangles in the brain.

Quest Diagnostics said Thursday that its Haystack Oncology subsidiary has entered a collaboration agreement with Rutgers Cancer Institute of New Jersey for a study of early-stage triple-negative breast cancer patients. Researchers will use Haystack's MRD technology to help evaluate therapeutic response and collect molecular information on individuals undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.

Secaucus-based Quest Diagnostics on Thursday said it was awarded a contract by the Centers for Disease Control and Prevention designed to assess the burden of hepatitis C virus in the U.S. The agreement marks a new phase of a decadelong collaboration between Quest and the CDC to improve hepatitis public health research based on insights from laboratory data.

Four local students from two academic institutions have been selected to participate in the American Heart Association’s Historically Black Colleges and Universities (HBCU) Scholars program, which is designed to help address racial disparity among medical students and physicians. According to the Association of American Medical Colleges, only eight percent of medical students and five percent of physicians are Black and African American. The program is funded by a grant provided by the Quest Diagnostics Foundation, which also supports the American Heart Association’s Hispanic Serving Institutes (HSI) Scholars Program.

Scipher Medicine and Quest Diagnostics have announced a multiyear collaboration to expand access to diagnostic services for patients with rheumatoid arthritis (RA).

Quest Diagnostics is teaming up with a Spain-based biotech to bring an advanced colorectal cancer screening blood test to the U.S. Under the new partnership, the Secaucus-headquartered testing provider will work with UDX to develop and seek U.S. Food and Drug Administration premarket approval for a novel “liquid biopsy” blood test to screen for colorectal cancer, the third leading cause of cancer death in the country, according to a Nov. 20 announcement.

For its third annual look-ahead, CLP recently asked a wide range of clinical laboratory experts to look into their professional crystal balls and make their predictions for 2024.

In honor of National Alzheimer’s Awareness Month, held November 2023, Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions.

Quest Diagnostics recently launched Quest Mobile™, which the Secaucus-based health care company says will make it easier and more convenient for patients to have a specimen collected for lab testing nationwide. Patients can request an appointment for at-home specimen collection with a trained Quest Mobile phlebotomist for a broad range of laboratory tests in the comfort of their home.

Michael McPhaul, MD, is senior medical director of endocrinology at Quest Diagnostics and editor of the Journal of Investigative Medicine High Impact Case Reports. His work at Quest Diagnostics focuses on the development of new tests for biomarkers of metabolic health to improve prevention, early diagnosis, and monitoring for patients with cardiometabolic health conditions. Here, he discusses advances in insulin resistance testing.